Advertisement
Dr. Bruno will join other leading experts from industry, government andacademia in a scientific program that will discuss the latest methodologies inpharmacometrics, focusing on pharmacokinetic and pharmacodynamic (PK/PD)modeling and simulation in drug development, regulation and clinicalapplications. The symposium will also provide a forum for scientificdiscussion and collaborative exchange on model-based approaches in drugdevelopment. Dr. Bruno's presentation, discussing a model-based approach tosupport drug development in oncology, will be part of a session focusing onthe theory and applications of model-based drug development. The presentation,entitled "Clinical Trial Simulations to Predict Efficacy and Survival Benefitof Anticancer Agents", will take place on October 29, 2007. Dr. Bruno alsoserves on the symposium's international advisory committee.
Advertisement
"Model-based drug development continues to grow as a value-added methodfor optimizing decisions in the drug development process," said Shawn O'Connor,president, CEO, and chairman of Pharsight. "Drug development is benefitingfrom the quantitative application of drug-disease models to simulate expectedclinical responses of new compounds, to support critical program strategiesand enhance study design decisions. Pharsight is pleased to participate atthis important international symposium, to discuss opportunities andchallenges for global drug development and approval in the rapidly-growingChinese pharmaceutical industry, and to exchange information with industrycolleagues on the strategic use of modeling and simulation."
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products andservices that enable pharmaceutical and biotechnology companies to achievesignificant and enduring improvements in the development and use oftherapeutic products. Pharsight's goal is to help customers reduce the time,cost and risk of drug development, as well as optimize the post-approvalmarketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug developmentsuccess: strong decision-making. By adopting the Pharsight approach, customersacquire a new decision-making process with the potential to systematicallyimprove every level and phase of their business and scientific processes.Pharsight Corporation is headquartered in Mountain View, California.Information about Pharsight is available at http://www.pharsight.com.
Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation. All otherbrand or product names mentioned in this documentation are trademarks orregistered trade marks of their respective companies or organizations.
SOURCE Pharsight Corporation
